> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Trump Plan Wants Pricing Disclosed in DTC Ads
- URL: https://www.fdaweb.com/trump-plan-wants-pricing-disclosed-in-dtc-ads/
- Published: 2018-05-11T12:00:00.000Z
- Updated: 2026-09-15T00:04:37.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141415

President Trump’s just-released blueprint for lowering prescription drug prices orders FDA to require drug companies advertising their drugs to include pricing information in the advertisements. HHS secretary **Alex Azar**, who joined the president in a 5/11 Rose Garden announcement, had this to say: “Think about all the time everybody spends watching drug company ads, and how much information companies are required to put in them. If we want to have a real market for drugs, why not have them disclose their prices in the ads, too? Consumers would have much more balanced information, and companies would have a very different set of incentives for setting their prices. We’re immediately going to look into having the FDA require this.”

The [blueprint](https://www.whitehouse.gov/briefings-statements/president-donald-j-trumps-blueprint-lower-drug-prices/?ref=fdaweb.com) includes 50 actions the Trump Administration is willing to take to lower drug costs to consumers. These include:

- Taking steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect monopolies.
- Advancing biosimilars and generics to boost price competition.
- Streamlining and accelerating the approval process for over-the-counter drugs.
- Speeding access to, and lower the cost of, new drugs by clarifying policies for sharing information between insurers and drug makers.